Psilocybin and Obsessive-Compulsive Disorder: Exploring New Therapeutic Horizons.
Neuroscience Bulletin May 14, 2025
Psilocybin and Obsessive-Compulsive Disorder: Exploring New Therapeutic Horizons.
Page 224 of 401: studies 2,231 to 2,240 of 4,004, newest first. Back to the serotonin overview
Neuroscience Bulletin May 14, 2025
Psilocybin and Obsessive-Compulsive Disorder: Exploring New Therapeutic Horizons.
Quality in Sport May 12, 2025 Izabela Zajkowska, Patrycja Niczyporuk, Aleksandra Giba et al. 1 citation
This review explores an innovative, integrative therapeutic approach that combines probiotics, prebiotics, and mindfulness-based interventions (MBIs) to target the dysregulation of the gut–brain axis in schizophrenia. The rationale for this combined strategy is rooted in the overlapping mechanisms by which both biological and psychosocial interventions influence neurophysiological processes....
Alcoholism Treatment Quarterly May 2, 2025 Ritika Shah, Ashish Sarangi
ABSTRACT Background Alcohol Use Disorder (AUD) is a widespread condition with serious health, social, and economic impacts, often marked by relapse despite the availability of FDA-approved treatments. Recent studies suggest that psychedelic substances, such as psilocybin, Lysergic acid diethylamide (LSD), ayahuasca, etc. may offer novel therapeutic potential in treating AUD by modulating...
Medicine May 2, 2025 Xiaobo Bi, Junchao Dai, Jin Li 8 citations
This study aimed to investigate the effects of a single intravenous injection of esketamine during general anesthesia on postoperative anxiety and depression in patients with thyroid cancer. In this randomized, double-blind, placebo-controlled, parallel-group trial, eighty female patients with thyroid cancer were scheduled to undergo surgery under general anesthesia. The patients were randomly...
Physiology May 1, 2025 Andres Villegas Calderon, Emma R. Huels, Amanda Nelson et al.
Serotonergic psychedelics are being explored as therapeutic agents for mental health disorders and have also been shown to promote wakefulness. In a recently completed study (reported as preliminary findings), we showed that intravenous administration of 2,5-Dimethoxy-4-iodoamphetamine (DOI), a classic serotonergic psychedelic, can induce wakefulness and reverse the state of anesthesia produced...
May 1, 2025 Jessi Humphreys, Lou Lukas, Yvan Beaussant et al.
Abstract Psilocybin, a naturally occurring psychoactive compound found in more than 200 mushroom species, has an enduring history of use in sacred rituals of Indigenous healers worldwide. With selective serotonin receptor binding, activation of the serotonergic neurological system enables psilocybin to potentiate neuroplasticity, enabling individuals to engage in meaning-making from psychedelic...
International Clinical Psychopharmacology May 1, 2025 Vincenzo Cardaci, Matteo Carminati, Mattia Tondello et al. 7 citations
Postpartum depression (PPD) is an increasingly prevalent but still poorly characterized disorder. Causal and modulating factors include hormones fluctuations, such as estrogen, progesterone, and allopregnolone, pathways imbalances, such as oxytocin and kynurenine, chronobiological factors, and brain imaging alterations. Treatment may differ from the traditional major depression management,...
Diabetes, Obesity & Metabolism May 1, 2025 Ariana Ramirez, Stephanie Howes, Robert Chilton 3 citations
Ketamine, a dissociative anaesthetic, has expanded its clinical use beyond anaesthesia to pain management and treatment-resistant depression. As an N-methyl-d-aspartate receptor antagonist, ketamine disrupts the excitatory neurotransmission via interaction with the opioid, alpha-amino-3-hydroxy-5-methyl-4-isooxazole-propionic acid receptor and serotonin pathways, contributing to its broad...
Pharmacological Reviews May 1, 2025 Merel Dagher, Catherine M Cahill, Anne M. Andrews 10 citations
We aimed to review clinical research on the safety profiles of antidepressant drugs and associations with maternal depression and neonatal outcomes. We focused on neuroendocrine changes during pregnancy and their effects on antidepressant pharmacokinetics. Pregnancy-induced alterations in drug disposition and metabolism impacting mothers and their fetuses are discussed. We considered evidence...
Advanced Science May 1, 2025 Yuanpeng Li, Hongyuan Li, Hongshuang Wang et al. 3 citations
The surge of new psychoactive substances (NPS) poses significant public health challenges due to their unregulated status and diverse effects. However, existing in vivo models for evaluating their activities are limited. To address this gap, this study utilizes the model organism Caenorhabditis elegans (C. elegans) to evaluate the activity of amphetamine-type stimulants (ATS) and their analogs....